ABBV-399: Phase Ib data

Data from 10 evaluable patients with c-MET-positive non-small cell lung cancer (NSCLC) in an open-label, dose-escalation, U.S. and French Phase I/Ib trial showed that ABBV-399 led to 3 partial respons...